{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:25:38Z","timestamp":1783689938606,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jns.2024.123311","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T16:35:52Z","timestamp":1731774952000},"page":"123311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Disease characteristics of NMOSD and their relationship with disease burden: Observations from a large single-center cohort"],"prefix":"10.1016","volume":"467","author":[{"given":"Suban","family":"Amatya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erum","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Kagzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema","family":"Akkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitiz","family":"Sriwastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.123311_bb0005","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/460825","article-title":"Neuromyelitis optica: an antibody-mediated disorder of the central nervous system","volume":"2012","author":"Oh","year":"2012","journal-title":"Neurol. Res. Int."},{"key":"10.1016\/j.jns.2024.123311_bb0010","series-title":"Neuromyelitis Optica Spectrum Disorder (NMOSD). StatPearls","author":"Shumway","year":"2024"},{"issue":"2","key":"10.1016\/j.jns.2024.123311_bb0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin. Med. (Lond.)"},{"issue":"14","key":"10.1016\/j.jns.2024.123311_bb0020","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1177\/1352458517735191","article-title":"Epidemiology of NMOSD in Catalonia: influence of the new 2015 criteria in incidence and prevalence estimates","volume":"24","author":"Sep\u00falveda","year":"2018","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.jns.2024.123311_bb0025","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jnnp-2016-314839","article-title":"Incidence and prevalence of NMOSD in Australia and New Zealand","volume":"88","author":"Bukhari","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2024.123311_bb0030","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann. Neurol."},{"issue":"24","key":"10.1016\/j.jns.2024.123311_bb0035","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006645","article-title":"Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark","volume":"91","author":"Papp","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123311_bb0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.msard.2017.10.007","article-title":"Neuromyelitis optica spectrum disorders in Iran","volume":"18","author":"Eskandarieh","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.jns.2024.123311_bb0045","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/ICU.0000000000000703","article-title":"Update on neuromyelitis optica spectrum disorder","volume":"31","author":"Holroyd","year":"2020","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"7","key":"10.1016\/j.jns.2024.123311_bb0050","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.jns.2024.123311_bb0055","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jns.2024.123311_bb0060","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation"},{"issue":"9451","key":"10.1016\/j.jns.2024.123311_bb0065","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jns.2024.123311_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cells8020090","article-title":"Aquaporin-4 water channel in the brain and its implication for health and disease","volume":"8","author":"Mader","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.jns.2024.123311_bb0075","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"9","key":"10.1016\/j.jns.2024.123311_bb0080","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.jns.2024.123311_bb0085","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20081241","article-title":"Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2","volume":"205","author":"Hinson","year":"2008","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.jns.2024.123311_bb0090","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2024.123311_bb0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jns.2024.123311_bb0100","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.jns.2024.123311_bb0105","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2024.123311_bb0110","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/WNO.0000000000000396","article-title":"Finding NMO: the evolving diagnostic criteria of neuromyelitis optica","volume":"36","author":"Bennett","year":"2016","journal-title":"J. Neuroophthalmol."},{"issue":"2","key":"10.1016\/j.jns.2024.123311_bb0115","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40120-022-00432-x","article-title":"Characterization of disease severity and stability in NMOSD: a global clinical record review with patient interviews","volume":"12","author":"Capobianco","year":"2023","journal-title":"Neurol. Ther."},{"issue":"3","key":"10.1016\/j.jns.2024.123311_bb0120","article-title":"Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis","volume":"4","author":"Srikajon","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"9","key":"10.1016\/j.jns.2024.123311_bb0125","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jns.2024.123311_bb0130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","article-title":"Plasma exchange for severe attacks of CNS demyelination: predictors of response","volume":"58","author":"Keegan","year":"2002","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jns.2024.123311_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22062801","article-title":"Neuromyelitis optica spectrum disorder treatment-current and future prospects","volume":"22","author":"Waliszewska-Pros\u00f3\u0142","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jns.2024.123311_bb0140","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2024.123311_bb0145","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2024.123311_bb0150","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment: analysis of 36 patients","volume":"67","author":"Bichuetti","year":"2010","journal-title":"Arch. Neurol."},{"issue":"11","key":"10.1016\/j.jns.2024.123311_bb0155","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.jns.2024.123311_bb0160","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2024.123311_bb0165","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jns.2024.123311_bb0170","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/intimm\/dxx037","article-title":"Efficiency of antibody therapy in demyelinating diseases","volume":"29","author":"Akaishi","year":"2017","journal-title":"Int. Immunol."},{"issue":"1","key":"10.1016\/j.jns.2024.123311_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2024.123311_bb0180","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/ana.26623","article-title":"Aquaporin-4 antibody dynamics and relapse risk in seropositive neuromyelitis optica spectrum disorder treated with Immunosuppressants","volume":"93","author":"Yin","year":"2023","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123311_bb0185","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.jns.2024.123311_bb0190","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/bpa.12087","article-title":"Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status","volume":"23","author":"Sato","year":"2013","journal-title":"Brain Pathol."},{"issue":"7","key":"10.1016\/j.jns.2024.123311_bb0195","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1756285617709723","article-title":"Differential diagnosis of neuromyelitis optica spectrum disorders","volume":"10","author":"Kim","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.jns.2024.123311_bb0200","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40120-021-00253-4","article-title":"Neuromyelitis optica spectrum disorder: clinical burden and cost of relapses and disease-related care in US clinical practice","volume":"10","author":"Royston","year":"2021","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.jns.2024.123311_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.746959","article-title":"Serum aquaporin 4-immunoglobulin G titer and neuromyelitis optica spectrum disorder activity and severity: a systematic review and meta-analysis","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Neurol."},{"issue":"12","key":"10.1016\/j.jns.2024.123311_bb0210","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1007\/s00415-017-8635-4","article-title":"Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study","volume":"264","author":"Mariotto","year":"2017","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2024.123311_bb0215","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.jns.2024.123311_bb0220","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7224\/1537-2073.2022-049","article-title":"Hospital readmission rates in patients with neuromyelitis optica spectrum disorder","volume":"25","author":"Padarti","year":"2023","journal-title":"Int. J MS Care"},{"key":"10.1016\/j.jns.2024.123311_bb0225","article-title":"The costs of care from a US claims database in patients with neuromyelitis optica spectrum disorder","volume":"427","author":"Exuzides","year":"2021","journal-title":"J. Neurol. Sci."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24004477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24004477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T09:25:25Z","timestamp":1733909125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24004477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":45,"alternative-id":["S0022510X24004477"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123311","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease characteristics of NMOSD and their relationship with disease burden: Observations from a large single-center cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123311"}}